Kathryn Glass, co-head of the high-yield fixed-income group at Federated Hermes, embodies the unexpected trajectories that professionals can take in finance. With a background in Japanese language and literature, Glass’s journey is a testament to the idea that paths can diverge in unexpected ways. Initially, she ventured into academia, collecting degrees from institutions like the
In a remarkable financial feat, Huawei has reported a revenue of 862.1 billion Chinese yuan (approximately $118.2 billion) for the year 2024, showcasing a staggering 22.4% year-on-year increase. This figure, while the second-highest in the company’s history, falls short of its 2020 peak of 891.4 billion yuan. The narrative here is one of a company
In an era where mainstream accessibility is reshaping the investment landscape, major financial institutions like JPMorgan Chase and BlackRock are aggressively pushing strategies once reserved for elite private banking circles into the hands of everyday investors. This transition isn’t just a financial upgrade—it’s rebellious capitalism at its finest. Wall Street seems determined to democratize investment
When Wes Moore, the Governor of Maryland, reflected on his formative years, he recounted a pivotal moment at the age of eight when his mother considered sending him to military school as a means of correcting his behavior. It wasn’t until five turbulent years later that he stepped into military school, enduring a rocky start
The turbulent economic landscape often leads investors into a state of paralysis as market fluctuations send tremors through stock valuations. Amidst the uncertainty—heightened by tariffs introduced under the Trump administration—one might expect to see panic dominate trading floors. However, volatilities can also create ripe opportunities for astute investors willing to identify strong stocks poised for
In a pivotal move that could redefine diabetes management, Novo Nordisk’s Rybelsus has showcased significant cardiovascular benefits, presenting a formidable case for this oral medication in an arena traditionally dominated by injectables. Announced at the American College of Cardiology’s Annual Scientific Session, the study results reveal that Rybelsus reduces the risk of cardiovascular-related mortality, heart
Illumina, a titan in the realm of genomic testing, has witnessed remarkable highs and crushing lows within a short span of time. Once hailed as a pandemic savior with revenues soaring from $3.2 billion to an impressive $4.5 billion from 2020 to 2021, the company is now grappling with a decline that feels almost cruel.
The expiration of Vanguard’s patent in 2023 could very well herald a new era in the exchange-traded fund (ETF) industry. Traditionally deemed a cornerstone of Vanguard’s competitive advantage, this patent was instrumental in enabling tax-efficient investing strategies that have been largely exclusive to the firm. Now that the doors have swung wide open, other players